Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 4/20 | 1.00 |
| ▸ | F10 | P00742 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.55 |
| ▸ | MMP13 | P45452 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387276 | 0.97 | LSS (0.94) | LSSF10CHRM1CNR1MMP2 | |
| SCHEMBL1387358 | 0.90 | LSS (0.81) | LSSF10CHRM1MAPK1 | |
| SCHEMBL6180061 | 0.89 | LSS (0.80) | LSSF10CHRM1CNR1SMN1; SMN2 | |
| SCHEMBL7660042 | 0.87 | LSS (0.77) | LSSF10CNR1MAPTSMN1; SMN2 | |
| SCHEMBL1387298 | 0.87 | LSS (0.88) | LSSF10CHRM1CNR1SMN1; SMN2 | |
| SCHEMBL6786388 | 0.86 | LSS (0.76) | LSSF10CHRM1MAPTMAPK1 | |
| SCHEMBL6181000 | 0.86 | LSS (0.76) | LSSF10CHRM1CNR1MMP2 | |
| SCHEMBL1387325 | 0.86 | F10 (0.77) | LSSF10CHRM1CNR1MAPT | |
| SCHEMBL6793676 | 0.86 | LSS (0.74) | LSSF10CHRM1MAPTMAPK1 | |
| SCHEMBL6791070 | 0.85 | LSS (0.77) | LSSF10CHRM1CNR1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0844877-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1998-06-03 | — | — | EP | claimed |
| WO-1997006802-A1 | USE OF OXIDO-SQUALENE CYCLASE INHIBITORS TO LOWER BLOOD CHOLESTEROL | ZENECA LIMITED (GB) | 1997-02-27 | — | — | WO | claimed |
| US-6440972-B1 | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| US-6335341-B1 | ANTICHOLESTEROL AGENTS; ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2002-01-01 | — | — | US | disclosed |
| EP-1000057-A1 | PYRIDYL- AND PYRIMIDYL-HETEROCYCLIC COMPOUNDS INHIBITING OXIDO SQUALENE-CYCLASE | AstraZeneca UK Limited (GB) | 2000-05-17 | — | — | EP | disclosed |
| EP-0966460-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS OXIDO-SQUALENE CYCLASE INHIBITORS | ZENECA LIMITED (GB) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999006395-A1 | PYRIDYL- AND PYRIMIDYL-HETEROCYCLIC COMPOUNDS INHIBITING OXIDO SQUALENE-CYCLASE | ZENECA LIMITED (GB) | 1999-02-11 | — | — | WO | disclosed |
| WO-1998035956-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS OXIDO-SQUALENE CYCLASE INHIBITORS | ZENECA LIMITED (US) | 1998-08-20 | — | — | WO | disclosed |